跳至主要内容
临床试验/NCT01002716
NCT01002716Unknown4 期

Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis

Tel-Aviv Sourasky Medical Center2 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2009年10月最近更新:
适应症

试验速览

阶段
4 期
入组人数
90
试验地点
2
主要终点
Cell immunity response

研究概览

简要总结

The efficacy of vaccination against influenza in patients with rheumatoid arthritis has been assessed using humoral response. However, the cellular immunity is another important pathway of response to vaccination. The purpose of this study is to evaluate the degree of cellular immunity response to influenza vaccination. Patient with rheumatoid arthritis and healthy controls will participate in this study , will undergo a clinical evaluation the day of vaccination and 4 weeks after. The humoral and cell immunity response will be assessed the day of vaccination and 4 weeks later

详细描述

Sixty patients with RA and 30 healthy , aged matched controls will participate in the study.

After signing informed consent, all subjects will be vaccinated with the inactivated split virion vaccine which will be recommended by the WHO next fall.

Patients will be evaluated at weel 0 and 6 weeks later. Clinical evaluation will be based on the Disease Activity Score 28 (DAS 28) which includes number of swollen and tender joints, visual global evaluation of the physician , ESR and CRP Blood with be collected on the day of vaccination and 6 weeks later.

Preparation of peripheral blood mononuclear cells Blood samples will be obtained prior to and 4 weeks after vaccination. Peripheral blood mononuclear cells (PBMC) will be isolated by centrifugation of heparinized blood on a Lymphoprep gradient (Nycomed, Oslo, Norway). Cells will be washed twice in tissue culture medium RPMI (RPMI1640-Hepes with Glutamax-I, GIBCO BRL, NY, USA) and resuspended to a concentration of 2 106/ml in RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum (FBS) (GIBCO BRL, NY, USA).

ELISPOT assay The 96-well PVDF (polyvinylidene difluoride, Millipore Corp., MA, USA) plates will be prewet with 70% EtOH, then coated with 100 l/well of anti-human IFN- monoclonal antibody (mAb) 1-D1K , diluted to 15 g/ml in sterile filtered phosphate-buffered saline (PBS) . The plates will be kept overnight at 4°C. A total of 100 000 PBMC plus 5 l/well (1 g/ml) peptides will be added to each well in duplicate for each condition and incubated for 24 h at 37°C in 5% CO2. After incubation the plates will be washed with PBS then 100 l of biotinylated mAb (7-B6-1-biotin, Mabtech AB), diluted in filtered PBS with 0.5% FBS to the concentration 1 g/ml were added to each well. The plates will be incubated 2 h at room temperature, washed with PBS and then incubated with 100 l/well of streptavidine-alkaline phosphatase (Mabtech AB) diluted 1-1000 in PBS with 0.5% FBS for 1 h at room temperature. After washing, cells will be developed by adding 100 l/well of colorimetric substrate (BCIP/NBT-plus, Mabtech AB) and then counted in an ELISPOT reader. Each spot was produced by a single IFN- secreting T-cell-spot-forming cell (SFC). All tests were performed in duplicate and the mean values were calculated. A response will be considered to be positive when the number of spots in the wells with peptide-stimulated cells, after subtraction of the background (wells without peptide stimulation), will be at least two-fold greater than the number of background spots14 and more than 20/106 SFC.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Rheumatoid arthritis

排除标准

  • Allergy to egg

结局指标

主要结局

Cell immunity response

时间窗: 4 weeks

次要结局

  • Safety of influenza vaccination(4 weeks)

研究者

申办方类型
Other Gov

研究点 (2)

Loading locations...

相似试验